0000950170-24-056254.txt : 20240509 0000950170-24-056254.hdr.sgml : 20240509 20240509070538 ACCESSION NUMBER: 0000950170-24-056254 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240509 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Amylyx Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001658551 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464600503 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41199 FILM NUMBER: 24928503 BUSINESS ADDRESS: STREET 1: 43 THORNDIKE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 617-683-0917 MAIL ADDRESS: STREET 1: 43 THORNDIKE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02141 8-K 1 amlx-20240509.htm 8-K 8-K
0001658551false00016585512024-05-092024-05-09

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 9, 2024

AMYLYX PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-41199

46-4600503

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

43 Thorndike, St.,

Cambridge, MA

02141

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 682-0917

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

AMLX

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

Item 2.02 Results of Operations and Financial Condition.

On May 9, 2024, Amylyx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 hereto.

The information provided in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

 

Exhibit

Number

Description

 

 

 99.1

Press Release of the Company, dated May 9, 2024

 104

Cover Page Interactive Data File (embedded with the Inline XBRL document).

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

AMYLYX PHARMACEUTICALS, INC.

Date: May 9, 2024

By:

/s/ James M. Frates

James M. Frates

Chief Financial Officer

 

 EX-99.1 2 amlx-ex99_1.htm EX-99.1 EX-99.1

 

 

Exhibit 99.1

 

Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results

 

˗
Company plans to engage with FDA based on interim data from the Phase 2 HELIOS clinical trial demonstrating improvements in pancreatic function, glycemic control, and vision in participants with Wolfram syndrome treated with AMX0035; topline data from all 12 participants at Week 24 anticipated in fall of 2024

 

˗
Interim analysis from the ORION study of AMX0035 in progressive supranuclear palsy continues to be expected in mid-2025

 

˗
Amylyx expects to initiate clinical trial of AMX0114 in ALS in the second half of 2024

 

˗
Cash, cash equivalents and short-term investments of $373.3 million at March 31, 2024 provides expected cash runway into 2026

 

˗
Management to host conference call and webcast today at 8:00 a.m. Eastern Time

 

CAMBRIDGE, Mass. May 9, 2024 – Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the first quarter ended March 31, 2024.

 

“As an organization deeply committed to ending the suffering caused by neurodegenerative diseases, we took swift action in the first quarter of 2024 to focus our resources on key clinical and preclinical programs and build on the vital foundation we have laid to date as we drive toward our mission. We are focused on diseases where there is a high unmet need for better therapies and where there are well-defined measurable biomarkers, rigorous supporting preclinical data, and well-defined rationales for our therapy’s mechanism of action,” said Joshua Cohen and Justin Klee, Co-CEOs of Amylyx. “We anticipate multiple near-term catalysts for our pipeline, including data from our ongoing clinical trials of AMX0035 in Wolfram syndrome this fall and PSP in mid-2025. We are also excited to bring AMX0114, our potent antisense oligonucleotide targeting inhibition of calpain-2, to the clinic in ALS in the second half of 2024.”

 

Recent Corporate Updates:

 

•
Amylyx announced formal intention to remove RELYVRIO®/ALBRIOZA™ from the market based on topline results from the Phase 3 PHOENIX trial. In April, the Company announced that it started a process with the U.S. Food and Drug Administration (FDA) and Health Canada to voluntarily discontinue the marketing authorizations for RELYVRIO/ALBRIOZA for the treatment of ALS and remove the product from the market in the U.S. and Canada. This decision was informed by topline PHOENIX trial results, engagement with regulatory authorities, and discussions with the ALS community. As of April 4, 2024, RELYVRIO/ALBRIOZA is no longer available for new patients, and patients currently on therapy in the U.S. and Canada who, in consultation with their physician, wish to stay on treatment can be transitioned to a free drug program. Amylyx also announced a restructuring to focus the Company’s financial resources on key programs and extend expected cash runway into 2026, through anticipated data readouts for AMX0035 in Wolfram syndrome and PSP, and AMX0114 in ALS.
•
Interim data from the ongoing Phase 2 HELIOS clinical trial of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO, also known as ursodoxicoltaurine]) in eight adults living with Wolfram syndrome demonstrated encouraging improvement in pancreatic beta cell function, glycemic control, and vision. Amylyx is planning to meet with FDA based on these interim data. Wolfram is a rare, progressive, genetic disease impacting approximately 3,000 people in the U.S. There are no approved treatment options for Wolfram. The majority of people with Wolfram carry mutations in the WFS1 gene, which encodes a protein called wolframin that spans the membrane of the endoplasmic reticulum (ER). Wolfram is considered a prototypical ER stress disorder because of the clear link between WFS1 mutations and ER stress. AMX0035, which targets ER stress and associated mitochondrial

1

 

 

dysfunction, has shown benefit in cellular models of the disease and a genetic animal model of the disease. The interim data from eight participants who have completed 24 weeks of treatment showed evidence of improvements in beta cell function and glycemic control, as measured by c-peptide and other markers of glucose metabolism, rather than the worsening typically expected with disease progression. All eight participants met prespecified responder criteria demonstrating either improvement or stabilization of disease according to both the Patient Reported Global Impression of Change (PGIC) and the Clinician Reported Global Impression of Change (CGIC) scales. The majority of participants reported some improvement in vision. AMX0035 was generally well-tolerated in all participants, and there have been no dropouts or discontinuations thus far. Amylyx anticipates reporting topline data from all 12 participants at Week 24 in the fall of 2024.
•
The Company hosted a virtual webcast with Dr. Fumihiko Urano to discuss interim data from the Phase 2 HELIOS clinical trial of AMX0035 in people living with Wolfram syndrome. Dr. Urano is a leading expert in Wolfram syndrome, the Principal Investigator of the Phase 2 HELIOS clinical trial in Wolfram syndrome, and the Samuel E. Schechter Professor of Medicine in the Division of Endocrinology, Metabolism & Lipid Research at Washington University School of Medicine in St. Louis. A replay is available at https://investors.amylyx.com.
•
Data from an interim analysis of the ORION study of AMX0035 in PSP are expected in mid-2025. ORION is a randomized, double-blind, placebo-controlled Phase 3 clinical trial designed to assess the efficacy, safety, and tolerability of AMX0035 in people living with PSP. PSP is a rare neurological disorder that affects body movements, walking and balance, and eye movement and is characterized by widespread neurodegeneration associated with tau protein deposition in subcortical regions of the brain. PSP is considered a tauopathy based on the strong genetic linkage of tau variants to the disease and presence of tau pathology in post-mortem brain samples. Variants in ER stress-linked genes have also been associated with the disease. In addition to demonstrating that AMX0035 targets ER stress and mitochondrial dysfunction, AMX0035 has been shown to significantly reduce cerebrospinal fluid (CSF) tau in a Phase 2, randomized, placebo-controlled trial in Alzheimer’s disease. There are currently no approved therapies for the treatment of PSP, and the disease is reported to affect seven in 100,000 people worldwide.
•
The Company plans to file an investigational new drug (IND) application, then initiate a multiple ascending dose clinical trial of AMX0114 in people living with ALS in the second half of 2024. Amylyx has completed IND-enabling studies of AMX0114, a potent antisense oligonucleotide targeting inhibition of calpain-2, a well-established target in a number of neurological diseases and a protease known to cleave many substrates including neurofilament, tau, and TDP43 proteins. Amylyx has observed rescue of cellular degeneration and neurofilament biology in multiple cellular experiments with AMX0114.
•
Bernhardt G. Zeiher, MD, FCCP, FACP, appointed to Amylyx Board of Directors. Dr. Zeiher has spent more than 20 years in drug development at companies including Astellas Pharma, Pfizer, Eli Lilly and Company, and Merck and oversaw the approval of 15 new treatments that addressed people’s unmet needs in serious diseases with few to no treatment options.

 

 

Financial Results for the First Quarter Ended March 31, 2024

 

Net product revenue: Net product revenue was $88.6 million for the three months ended March 31, 2024, compared to net product revenue of $71.4 million for the same period in 2023. During these periods, net product revenue was primarily related to units of RELYVRIO and ALBRIOZA sold in the U.S. and Canada, respectively. On April 4, 2024, the Company announced that it had started a process with the FDA and Health Canada to voluntarily discontinue the marketing authorizations for RELYVRIO/ALBRIOZA and remove the product from the market in the U.S. and Canada based on topline results from the Phase 3 PHOENIX trial.

Cost of Sales: Cost of sales were $116.4 million in the three months ended March 31, 2024, compared to cost of sales of $5.3 million for the same period in 2023. Cost of sales in the three months ended March 31, 2024 included non-cash charges of approximately $110.5 million associated with the write-down of inventory and loss on firm purchase

2

 

 

commitments related to the Company’s decision to voluntarily discontinue the marketing authorizations for RELYVRIO/ALBRIOZA in the U.S. and Canada. During these periods, cost of sales consisted of costs to procure, manufacture, and distribute RELYVRIO and ALBRIOZA.

R&D Expenses: Research and development expenses were $36.6 million for the three months ended March 31, 2024, compared to $24.2 million for the same period in 2023. The increase was primarily driven by an increase in personnel-related expenses due to added headcount to support research and development efforts, an increase in spending on the Phase 3 ORION study of AMX0035 in PSP, and an increase in preclinical development activities.

SG&A Expenses: Selling, general and administrative expenses were $57.8 million for the three months ended March 31, 2024, compared to $44.0 million for the same period in 2023. The increase was primarily driven by higher personnel-related expenses due to added headcount to support the Company’s launch, commercialization initiatives, and operations as a public company, and other expenses.

Net Loss: Net loss for the three months ended March 31, 2024 was $118.8 million, or $1.75 on a fully diluted per share basis, compared to a net income of $1.6 million, or $0.02 on a fully diluted per share basis for the same period in 2023.

Cash Position: Cash, cash equivalents, and short-term investments were $373.3 million at March 31, 2024, compared to $371.4 million at December 31, 2023. The Company expects cash runway into 2026, which will allow the organization to deliver on key upcoming milestones, including anticipated data readouts from HELIOS (AMX0035 in Wolfram syndrome), ORION (AMX0035 in PSP), and its planned trial of AMX0114 in ALS.

 

3

 

 

Investor Conference Call Information

Amylyx’ management team will host a conference call and webcast today, May 9, 2024, at 8:00 a.m. ET to discuss financial results and provide an update on the business. To access the conference call, please dial +1 (877)-346-6112 (U.S. & Canada) or +1 (848)-280-6350 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/news-events/events. The webcast will be archived and available for replay for 90 days following the event.

 

Available Information

We periodically provide other information for investors on our corporate website, https://amylyx.com, and our investor relations website, https://investors.amylyx.com. This includes press releases and other information about financial performance, information on corporate governance, and details related to our annual meeting of stockholders. We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor our website, in addition to following the Company’s press releases, SEC filings, and public conference calls and webcasts.

 

About AMX0035

AMX0035 is an oral, fixed-dose combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO; also known as ursodoxicoltaurine outside of the U.S.). AMX0035 was designed to slow or mitigate neurodegeneration by targeting endoplasmic reticulum (ER) stress and mitochondrial dysfunction, two connected central pathways that lead to cell death and neurodegeneration. Preclinical studies have provided evidence that AMX0035 may reduce cell death and improve cellular function, also supporting the synergistic effect of AMX0035 compared to individual compounds. AMX0035 is being studied as a potential treatment in neurodegenerative diseases, including Wolfram syndrome and progressive supranuclear palsy (PSP).

 

About AMX0114
 

AMX0114 is an antisense oligonucleotide designed to target the gene encoding calpain-2, a key contributor to the axonal (Wallerian) degeneration pathway. Axonal degeneration has been recognized as an important early contributor to the clinical presentation and pathogenesis of ALS and other neurodegenerative diseases. Calpain-2 has been implicated in the pathogenesis of ALS based on findings of elevated levels of calpain-2 and its cleavage products in postmortem ALS tissue, therapeutic benefit of calpain-2 modulation in animal models of ALS, and the role of calpain-2 in cleaving neurofilament, a broadly researched biomarker in ALS. Preclinical studies completed to date have shown that AMX0114 achieves potent, dose-dependent, and durable knockdown of CAPN2 mRNA expression and calpain-2 protein levels in human motor neurons. Moreover, in preclinical efficacy studies, treatment with AMX0114 reduced extracellular neurofilament light chain levels following neurotoxic insult in induced pluripotent stem cell (iPSC)-derived human motor neurons, and improved survival of iPSC-derived human motor neurons harboring ALS-linked, pathogenic TDP-43 mutations.

 

About the HELIOS Trial
 

The HELIOS trial (NCT05676034) is a 12-participant, open-label Phase 2 trial designed to study the effect of AMX0035 on safety and tolerability, and various measures of endocrinological, neurological, and ophthalmologic function in adult participants living with Wolfram syndrome.

 

About Wolfram Syndrome
 

Wolfram syndrome is an autosomal recessive neurodegenerative disease characterized by childhood-onset diabetes, optic nerve atrophy, and neurodegeneration. Common manifestations of Wolfram include diabetes mellitus, optic nerve atrophy, central diabetes insipidus, sensorineural deafness, neurogenic bladder, and progressive neurologic difficulties. Literature suggests approximately 3,000 people are living with Wolfram syndrome in the United States. Genetic and experimental evidence suggests that endoplasmic reticulum (ER) dysfunction is a critical pathogenic component of Wolfram. The prognosis of Wolfram is poor, and many people with the disease die prematurely with severe neurological disabilities.

4

 

 

 

About the ORION Trial
 

The ORION trial (NCT06122662) is a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial designed to assess the efficacy, safety, and tolerability of AMX0035 compared to placebo in people living with progressive supranuclear palsy (PSP). ORION was designed and planned in collaboration with key global academic leaders, people living with PSP and their caregivers, and industry advocacy organizations.

 

About PSP
 

Progressive supranuclear palsy (PSP) is a sporadic, rare, and adult-onset neurodegenerative disorder that affects walking and balance, eye movement, swallowing, and speech. People living with PSP have a life expectancy of six to eight years after initial diagnosis, and its epidemiology is similar to that of amyotrophic lateral sclerosis (ALS). PSP typically begins in late-middle age and rapidly progresses over time. The disease affects approximately seven in 100,000 people worldwide, and there are currently no disease-modifying therapies approved for the treatment of PSP.

PSP is characterized by abnormal tau inclusions and is consequently also known as a tauopathy. Similar to other neurodegenerative diseases, pathophysiologic changes underlying PSP are multifactorial, with several genetic and environmental factors likely contributing to tau dysfunction and aggregation.

Multiple pathways, including genetic mutations, endoplasmic reticulum (ER) stress, and the activation of unfolded protein response, mitochondrial dysfunction, and neuroinflammation have been implicated as contributors to tau dysfunction and aggregation.

 

About ALS
 

Amyotrophic lateral sclerosis (ALS, also known as motor neuron disease) is a relentlessly progressive and fatal neurodegenerative disorder caused by motor neuron death in the brain and spinal cord. Motor neuron loss in ALS leads to deteriorating muscle function, the inability to move and speak, respiratory paralysis, and eventually, death. More than 90% of people with ALS have sporadic disease, showing no clear family history. ALS affects around 30,000 people in the U.S., and more than 30,000 people are estimated to be living with ALS in Europe (European Union and the United Kingdom). People living with ALS have a median survival of approximately two years from diagnosis.

 

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. is committed to supporting and creating more moments for the neurodegenerative disease community through the discovery and development of innovative new treatments. Amylyx is headquartered in Cambridge, Massachusetts. For more information, visit amylyx.com and follow us on LinkedIn and X, formerly known as Twitter. For investors, please visit investors.amylyx.com.

 

Forward-Looking Statements

Statements contained in this press release and related comments in our earnings conference call regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, the potential of AMX0035 (sodium phenylbutyrate and taurursodiol) as a treatment for Wolfram syndrome and PSP or other neurodegenerative diseases; expectations regarding the timing of the announcement of results from the Company’s Phase 3 ORION trial of AMX0035 for the treatment of PSP, and additional results from the Company’s Phase 2 HELIOS trial of AMX0035 for the treatment of Wolfram syndrome, including planned discussions with regulatory authorities related to the latter; the potential for AMX0114 as a treatment for ALS and the planned initiation of a trial evaluating AMX0114 in ALS; the availability of RELYVRIO/ALBRIOZA for patients currently taking RELYVRIO/ALBRIOZA; the timing and significance of learnings from the PHOENIX trial; the Company’s expectations regarding its financial performance; expectations regarding the contributions of the Company’s board of directors; and expectations regarding the Company’s cash runway and longer-term strategy. Any forward-looking statements in this press release and related comments in the Company's earnings conference call are

5

 

 

based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of Amylyx’ program development activities; Amylyx’ ability to execute on its regulatory development plans and expectations regarding the timing of results from its planned data announcements and initiation of clinical studies; the risk that early-stage results may not reflect later-stage results; Amylyx’ ability to fund operations, and the impact that global macroeconomic uncertainty, geopolitical instability, and public health events will have on Amylyx’ operations, as well as the risks and uncertainties set forth in Amylyx’ United States Securities and Exchange Commission (SEC) filings, including Amylyx’ Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent filings with the SEC. All forward-looking statements contained in this press release and related comments in our earnings conference call speak only as of the date on which they were made. Amylyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

 

6

 

 

 

img212534189_0.jpg 

 

AMYLYX PHARMACEUTICALS, INC.

 

CONDENSED CONSOLIDATED BALANCE SHEETS

 

UNAUDITED

 

(in thousands)

 

 

 

 

March 31, 2024

 

 

December 31, 2023

 

Assets

 

 

 

 

 

 

Cash, cash equivalents and short-term investments

 

$

373,293

 

 

$

371,362

 

Accounts receivable, net

 

 

20,351

 

 

 

40,050

 

Inventories

 

 

—

 

 

 

83,280

 

Prepaid expenses and other current assets

 

 

16,890

 

 

 

14,931

 

Other assets

 

 

6,923

 

 

 

7,831

 

Total assets

 

$

417,457

 

 

$

517,454

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$

89,327

 

 

$

79,785

 

Other liabilities

 

 

3,694

 

 

 

4,237

 

Total liabilities

 

 

93,021

 

 

 

84,022

 

Stockholders’ equity

 

 

324,436

 

 

 

433,432

 

Total liabilities and stockholders' equity

 

$

417,457

 

 

$

517,454

 

 

AMYLYX PHARMACEUTICALS, INC.

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

 

UNAUDITED

 

(in thousands, except share and per share data)

 

 

 

 

Three Months Ended March 31,

 

 

2024

 

 

2023

 

Product revenue, net

 

$

88,643

 

 

$

71,428

 

Operating expenses:

 

 

 

 

 

 

Cost of sales

 

 

5,945

 

 

 

5,283

 

Cost of sales - inventory impairment and loss on firm purchase commitments

 

 

110,461

 

 

 

—

 

Research and development

 

 

36,608

 

 

 

24,192

 

Selling, general and administrative

 

 

57,759

 

 

 

44,006

 

Total operating expenses

 

 

210,773

 

 

 

73,481

 

Loss from operations

 

 

(122,130

)

 

 

(2,053

)

Other income, net

 

 

3,579

 

 

 

3,456

 

(Loss) income before income taxes

 

 

(118,551

)

 

 

1,403

 

Provision (benefit) for income taxes

 

 

242

 

 

 

(170

)

Net (loss) income

 

$

(118,793

)

 

$

1,573

 

 

 

 

 

 

 

 

Net (loss) income per share

 

 

 

 

 

 

Basic

 

$

(1.75

)

 

$

0.02

 

Diluted

 

$

(1.75

)

 

$

0.02

 

Weighted-average shares used in computing net (loss) income per share

 

 

 

 

 

 

Basic

 

 

67,854,356

 

 

 

66,717,271

 

Diluted

 

 

67,854,356

 

 

 

70,863,665

 

 

7

 

 

Contacts

 

Media

Amylyx Media Team

+1 (857) 799-7274

amylyxmediateam@amylyx.com

 

Investors
Lindsey Allen
Amylyx Pharmaceuticals, Inc.
+1 (857) 320-6244
Investors@amylyx.com

8

 GRAPHIC 3 img212534189_0.jpg GRAPHIC begin 644 img212534189_0.jpg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end EX-101.SCH 4 amlx-20240509.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Entity Address, State or Province Trading Symbol Soliciting Material Entity Address, City or Town Written Communications Entity Central Index Key Entity Tax Identification Number Entity Registrant Name Entity Ex Transition Period Document Period End Date Entity Address, Postal Zip Code Entity Incorporation, State or Country Code Entity Incorporation State Country Code Local Phone Number City Area Code Pre-commencement Tender Offer Pre Commencement Tender Offer Cover [Abstract] Security Exchange Name Entity Emerging Growth Company Amendment Flag Securities Act File Number Entity Address, Address Line One Title of 12(b) Security Security 12b Title Document Type XML 6 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document and Entity Information
May 09, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 09, 2024
Entity Registrant Name AMYLYX PHARMACEUTICALS, INC.
Entity Central Index Key 0001658551
Entity Incorporation State Country Code DE
Securities Act File Number 001-41199
Entity Tax Identification Number 46-4600503
Entity Address, Address Line One 43 Thorndike, St.,
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02141
City Area Code (617)
Local Phone Number 682-0917
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol AMLX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.amylyx.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports amlx-20240509.htm amlx-20240509.xsd http://xbrl.sec.gov/dei/2023 false false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "amlx-20240509.htm": { "nsprefix": "amlx", "nsuri": "http://www.amylyx.com/20240509", "dts": { "inline": { "local": [ "amlx-20240509.htm" ] }, "schema": { "local": [ "amlx-20240509.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.amylyx.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_988314c5-fe50-4c71-b28f-c7c021e283da", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "amlx-20240509.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_988314c5-fe50-4c71-b28f-c7c021e283da", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "amlx-20240509.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.amylyx.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.amylyx.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.amylyx.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.amylyx.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.amylyx.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.amylyx.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.amylyx.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.amylyx.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.amylyx.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.amylyx.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.amylyx.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.amylyx.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.amylyx.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.amylyx.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.amylyx.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.amylyx.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.amylyx.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.amylyx.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.amylyx.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.amylyx.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.amylyx.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.amylyx.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.amylyx.com/20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0000950170-24-056254-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-056254-xbrl.zip M4$L#!!0 ( +(XJ5B;&T665Q, #"Q 1 86UL>"TR,#(T,#4P.2YH M=&WM/6M7X[:VW_LK=)C;#JR+$K\?@9FST@PSS2FO1>@ZT_NE2[9DHC..G=H. M).?7WRW9A@02 HD#"60^M#B6)>VG]DO2X3^'O1!=LR3E0 M^ K&CB(6AB/TE4BS4[>J#'TDI#RV[;B4;;4%,6JYR\GFF93FYIY MTVR\*9^8P'AKO0YHS T5K8'Q/]XI+EX[9'TMOGP0?L)^,3;LBD?SNI7%=,0 M%!<$+YM'<70*A$^X/_TSFB7U;-1G=6B(H[SE[:Q2/FU. (%:_WYRW/&[K$?P M?= INX?]E/FUJ_BZ#B_@6TV_A22-#4VU'\-JWN(.] Q#9Q,?E)W?05[/$A*E M09ST)/L*Q BNQ;HZUL_T01_K1-.PHF'5*CLAO7"2$J0W"D=#*42"ZQ53<Z\<)4# [Z!,JM$P#.?WAP8X?K7Y9J>YKA*MC3J8L-3;>P8P8:/!JF8E%5L3V@<41Z8A3& M&T<1@#UJ 3@)"=L19G9.>S KQJF8YIJH?UB:E-GZG*5-]2/14;IJ]CPW%<[)FV@C5/\1V= M^ YE9'RF35"I5*C5KR&Y6FR& 0E3]F!R]4F4)BQ@":P"+/U\*)1!(Y6R!P,A MJ1P:0H0_[:1 RU (HORMFXAY"#[%)4/6ABD%OI#=C_P:!3 2 M,T\%IOB420*63YR*YX"S!,EILZD"W&K_/DFN^Q]_+G^:[+T/"(MI^02J*,G$ M@O7Y=KURR^_NWMU.D\YH6KXIG\M!ZA.H*?%XB[CZF$S4073NBU"/1[C+Q#+7 M4&HFCX08W;;KEZV\.($>(Q@,O9*5XYB_ZV4$ L\ I_R]KJ H\ MYD(MWRKYNX#T>#AJ7/(>2Z69,0SO?=;H)PS?)*1_?R:/#@XCWW":=1L!SW"AM6!( M].#?85W, A#4GT3/"L#V80XL613PFYRB7AS2<4PX"V+BC]/VY=$7U+EL7AYU MWBL2.D>M/R[:E^VC#FJ>?D%'WUN_-4^_':'6VZ\V=PC M7Z%$[_I&X.=P6K:3'HJ<165TEM.VJD9:=1A95U'_>G9Q@J;Q[S/ZWIENSAD! M%88;PSHU+6P$AHM=#RP7AQ(C8)ZNJZJ[D-4V9@*6CK4TP]<"H=)Q*+CIOEE9 MN998=));+?$^M<2BJPJ8 Q='IY?HXNC\[.)R$Y:[MT^3\T&2#DB4H2Q&'>;+ M8*&JHSA!JKE+]U YK[^#\FC?IQT^S!H4?L$]&*4K/L.4 MC/ (4(%9M![D.B$CY.[+\/K+K?4+^_;;M7XS=='=4)JQH#B;CN+;GH,=3278 M<*@'%KCK8I,$BD],E[IZL*PXY^'B"W;%4Q&UST[A3:52.A?X631LGOQY_.=W M=/Y;\^*DV3KZX[+=:AYW]E'[M%5[,;%=>/:;'H&S1?!T(M(M#L%6Y:XYPR\=:9]+BR<"F1$O M9-.X0R0'2PJ*68C,(( @FN.0C.)!!CT/&3W(1U$5I0:4+#X 4$+23UDC97V2 M@#$U27/9M\PPP@22<#F>6LHL%A M/4ON3ZC(U4BB3R7'#4"+O821'PWY7RQ^F$+F^S.X9DG&?1(6K7(&N97%I,@0 M*6J>(GHYQ3LC*TH]2DW=P [S;&S8@86)H]K8(H1ZBF>KGE/1(MZ._#@!#T,F MW3L9\$TK'D19,FK%=-)"%X4 (J.7L7X27XM^*C'-9[I'+"0W)&%S5FV0*> C MNN'TM@G5+$^06M'!:--H@ E1P893;,)D M86'#4A13T9]!RD<4N[UV>CVW^-;+HIYI)4L%+<)]9UF7)>A?@X2GE,LXX#@A M*@>S9HNO7Q16\ (FUJ:]E2N-C>*$5MSK\514K"*ATE&N";9(FD!2^Z*#CGK] M,!ZQY*W)Q^1"@$[CVE3B3]/%SU# *U"XS@K]N:F0S<+@+Q]42SE8N<1LX5T[ M>"OT/)<2D"G0OK8Q2XGG.KKBXL!7'&SHOHU=S2/85ES/475'\1VO&F.V26G" MTK3XWS&/F+I*0U9'E]TXB2C_P?91)ZOM/\&@K9H8XI%+,2_/^+#E/XFLN]G>L#OR3 MYH*N>:G'9,!2J0DM-EWA3==EQNL&ZJIFY0U<%4UUUPZ)D) M2MTUL0HJW;54S2:D6A5R'J<9"?^/]V44<86!)DTUU%>)3+S NK]1KE9!>)&\ M.T] >?$^"='1D/D#L4\2G07@J;!TKG^Z52_OD'= 3R"A*!YU8.'_(A'VWJK$ M[C+AOWQP--4^2-$E"UF_&T=ET$=NZ T'@E50$S24Q.6JJL4L1F%54"WL^3KX M!X8%UBBQ&"8V 0-))]1R]667$F& "D J6CPJH,*NI=I[*[94JRS[JI;FBL-, MWV $$Q(0;-@.P:YIVY@1I@9Z8!JV[2Q+\^,8U-^YX.K*"R,Q'W$ U'# M%5TQBCK"TT7'),V*2NAM5=<[K.I:0A>]W@[J5I?Y/^2&"]+O)W$_X2([Z\5# MY+$POA%<+EX*YD<._AT%/!0V&D\1%UU0X/XL1BGO#<*,1"P>I.$(I23C:3"2 M7Q8?Q!X FJ=YB@T>R5U]Y #Z21")1N6[( YAFN/5 ]U MCZZKIDL)IGX 'H_O!M@U?(9-"LZ.:A-FJTN7]_P[X1DPEDCJ#Z(BI9L^K+[S MXCCT"(AW!DJFNO#$+Q]H$T7:E!PT6MG6>%FC9@S\%,"+>R72UM*\#4'9%0KZ#2 M0]%6#8)5;4RZ)_;7WLJVH=3REEOQ?F7Q-FW?=HGA8-MS*39<1T2Q+!6;Q#,M M5V'4MI<^D.(\86+E%B=[R7,IA&F?G 4!2[9BOG9B#L3"_ABUYJ[FJD&QMNOM M/4WH\[9;L7]EL:>*83 C,+!G*QHV'-W$C@.K.F'$M#2;:=0W*Q;[=IH.6+(5 M_K%_N;3HZ\79QCRH//#%$D8G:'5[%HI4U$4@#.C3 MV :?7C7XI#N/1)_4Q]Z9"WYHF$\):3DOLPUI,FZOR*-%\\C]:DNG5U^S<2E. M2A#(/\I^JL@Z\4JZ]\PCR1$6 QS"JHW!Y[.J ?O M=^<7L6TY_9UQ^FEQ;(E4AJRT#\$>@6[AESNC9<5NW+/7*6'8KT%]LNDR6]''_?M04Q1!7 M>KC8\1V*3=NV#,US+#-8.J)5ZL@RQ"'/=7L0Q1(+W,J/?SDE*25_HSD\NJK1 MOX6Q)^Y,8B'S,W1"DA\L>^]1F'9$19R,(6^$?%GY!-/\ 28.DV=1W"M+XBF" M"3(@UY7(J%TE\4W6%>&VOBA5(BFB+.!1?J1;GC17S"G'U]Z=6JNC72'!]H&H M@U?4 YD_+[^!T8!C^^),.%%NF(?N- ]K3SP1]W[?(IIW]_E8[[7G!Y0VDMA' M,PBWH@+S@-E$IQ[V-=O$AJIXV*/,P[9F@EO$ LNREM9M^?ZT$JYO$JQ6#M7D M0;0R.(;E)4&O@OHG1_/?,O^U@T?4QSXHC:FZB#^HCNR"II%*'#1-%,M8\2!E MLA6 6=1@BHO'N(P?Y[<."7:08X4C,?@-AZ$%\TPG?![=UZQ/?% MH6FBL;B9C9*$IGGU)9T5J-9WR6V@>EPCU=!]^M\C]+,*C9]GD=PK,QZ_"6FY M./<2LC ET+UF0?QJ@1N[NRH(V1!3GN0L(X+M@UYT4%X*)]X>/+C>ZC^#-./! MJ!Q%ML+ Y@?C]UYUDSMFNF)Y& &3 -:W!@EOR"@M(NC/OTAK-D7F7UNQ&C54 M\9:.=L9Z2*LIFK@T4%]"B.AOP?R_&"4ZW\P[_TNTM5\=C74!-W?ORVGGQP)3,%@D$0\[8II"&.R MRSV>(=>MJ0C,8);%U=#Z.1IL?0A]"0CCT>TEGG=K(%CYTHXN]T*();S$&2%%;6?IPR*82W*ZOS1)M_7]"/]'(> MD$RW,]YL9V]?+/:Q<&YN8+U'Z<#[C_ &8147C4-.9!:4Y\-G79*A-)_#/DP_ M*0#AXW#PVP/MX %,E]L+(<6&D'A\$\<8X\L]O_E.D'1V67'A)(T#)>=_W[[8 M%_%IUI?G:K.A9&ZQZ81E J%@Y\"LTORX;7]B>@ ^"$D^C06D_MV:HHY? MK"P.;1'%)+GV+[@Y70!'SU/O:V*IBVMG%@S'R/E3YA4QLX"8/$?K._.5_CS(U'N0?6Q!7U["/^ZGX!+A%+RA8(DBE,TYV]RN*8]5 MJ@B#[[%M5$K-?6K5B4?\'^#- JOC@@OSY&\UU9J2AZ:6\,W(P6IC6>A"')8X M=61S,K:%=G@SM0GYH0E/+?5-> M1$>V$OO:$ELU,@CJ)B*?27KA$+.AZ_ZEUKI9;S::9@G.;%_ZD;TP:8HNBL#F M9-QI'U$9HYIVZ279RO]KR+^J&&^"X[?B7STR6C& AL[)%4-M83T27QZZ^H5D M)+\=9)>!>TA%H%LFLX6DMR.A'=#W7R^.$2VNYYTH;]E*^):9M\A81V0L6'7X MPL'E;5G$IIWWN/@&W?:WT^;E'Q='G?>2]3H?J^G*2\[^'@!+YFG I^:?I]2J MT4$X0CX9B/HRF3!/Y)F88AB/H12 AA=Q),L>$=Y*(,LV98CV2;S)KRV)E^^N.O#6N\]W4U M[=[(@7%;4^9)R(!.Q9M/.]K.6T;,,S9G_7G\YW=T_EOSXJ39.OKCLMUJ'G?V M4?NTM5$.6H]3&K)-(M%6D+?(V"+C98\IVX:/ED7[%[!"&VAJL'[+E%5(Z!LQ M1W\=-5Z]X&6S,%9/Z^A?1(Q^4D-?A;(F-KFK]USMCJJC4@ MPI8CM\C8(F-^T4*7LV!L'U5^1>S4&O8%$YY5IY;>:\;SL.[%=/3YI\-Z-^N% MG_\?4$L#!!0 ( +(XJ5B,&2U]*PD -QH 1 86UL>"TR,#(T,#4P M.2YX]SFS@:_KY_A8Y^:><6@YVFVWCJ[/B<=L=S:9-)TMG.W=SL8) = M9D'R"DCL_WXE0 2!A!W;@#U/6\CWZ]>OS*_O3KRO? $R2!B]%(Z_=, M#4!D8\=%BY'V_5X?WT^F4^W7RY\^_4/7P=67Z3?P#3Z#L1VZ3_#*#6P/!Q&! MX.W]UW?@Q[_NKL&]_0A]"UQA._(A"H$.'L-P.32,Y^?GGC-W48"]**35!3T; M^P;0]=3XA$"+W0=75@C!<& .WNOFN6Y^?!CTAX.SH7G1^_C^;/!/TQR:9NXU MO%P3=_$8@K?V.\#>HG4C!#UO#;ZXR$*V:WG@GE?Z,Y@BNP?&G@?NV%L!N(,! M)$_0Z24V5X$S#!(?0HLL8/C-\F&PM&PXTG*>6/[:6Z]B%UB=YKEYH0$K#(D[ MBT+X!1/_"LZMR M'6H3^BBS/G;O0H>QZD-$B%,@]ILV!@B%$D3_(JEO-B-?# M9,$J,@VX"B$*W)D'=58,DIBT0!^PMDM>MWQOM1EL4I:Z*Q1]/DNK,OO&CZ_7 M26ORPIZ+_A1*YZ"99P9[/+,"R(M'@;ZPK&7VQMP*9G'I] $#<\8+.] 5/0Z@ MW5O@)X,^$ JRATXH8\<\-Y*'^:)N!6#:&4/:03+ JY*#*1W]BXL+(WZJ7?X$ M0-Q)7'^)20B2OG*-[;@=*BIC?^F\1IW=TOL#_:S?H\8T@*2]3 '7V \$;Z>= M0&2-O"L(WDBL]G-5O=)6W:K&0-5_V(7.+BKK+/6ZUU4J[>(&],* WZF$(!\A M+Q LA' 8U\MN\9O+I8OF.+E#[[$6&A+LP8?U$@)V\?UNNFD^,$)KA1'VUP9[ MP>#3-_]_C)S/*'3#]9361/P8@@9<.G=L59)CX^@<2!<"-_:C;[)_=)G(K1C9 MI842%].BU2\:%N>'7FO?^\% MEO*U]"9O(['E^ "+V?72&:?8M'=P7FO+QG/=\)' ^4ACRXG.K;&>^^8U-D+J MX$@+Z.#QTCE#<-::08_QE)9F$"LFG]B#>!KFUMV0O9"9$6N-UTJ'KJLOU685 M8ULHZK'QC(GH^?;SR1OZQQ^W!$ZP3PFQXS5^&@01) \, ;F9SV%F/$8[TK9Z MQ6@&>M)\8\>AHR6XIZ,%WI!;@I_<9'4LPJXLWA#D!V*Q,/5^[<^P)\$H/F\( M%(TS79L.?K3X2DDA-/24(),4:J.9)_3RACS@9[2IA7,E&P+Z.W%#.G;9V(B0 MFRRU@02FO%RC;$[HN"66-Z5C=O5ON%9R62S7*,@':S5U* "ZS4A(^A;Y,^F, M5%V^4=!W<.$&E#,4[\&46 O%&H7X>46G&;H=8Q3=TJ&,'25,2=&&H/)E.JGU M,W+8#EN"4UZNC:GI%M.=CO>F& (]I!W-B0=&S%A*(XO-&6?SB>NJII52DC54F_8_N&V%_TR(CE&UX MP/0'LP>VSZT8+%F1AD,*)E]41!+Q8QDD5I2)KO2*?=( D?[]7MR[4[9Q1*2[ MSTV;YC^\6;;MVDI08*:U2VI6MW-V06(8))9!;#I5;N(WCMTMNK4,X'7F&YBT MZ%N58+!C2#6*'7U(;0'16/UM4! O]FN!U!B(K0%JKG[\"CUC M/S^H42!:!8G9^OT1-8_]W'BQ!9BQ^L&7E9#]'/B\ B\&06*Q3B^D.LF.+F0? M=27& +46)T T-JT*ZLF!9M;$)J!& ;-:OR^5BLI^3@FF MIDXVY6%19MJQO6(S(+;3P#2<%Z%V!!S''\Q&[0RK!:E#;95:VB/5M3MJRAU! MA]NU&S$;X+_./U"1(;(+4:)V^"+K> MCN@S&X 9J9_Y%[5OOR[CPH EH )FK[& 6R(#'BA82B\ LPEN4*U#H"@7[JI< ML'!6CQEY?KK/IAYJ#,36FM@M,"UTWTT"L[$%UC$1%5^+V+Q6 M>KFAXK2$86.Z&BY#/<&0OCXGV-\RVZ8@T M,8HC+PN7;4)5ITMQO KI\F@Z2CF)2MI'"N)EF_ K4ZLX>+5FV3[SBH0KD7>9 M8-D^] UI6*(+59IE^Z[(D[-$#R0J9?O U2E;(GB%2MFF Y6)7!R]6IULG_NJ M]"[IO%E6)]MW8JND+]&;S?)=FVZI4L&X#U*!KDW L@0Q#K8DS+4)='/:F"(\ M/J; 6)I,EM%=4K!:C2#E)3:2YH%FU#[@B=4VZ@)8$JV,8GL6$MN+0%$2>8PBX\FENQ3@KTW7RA]MR M&@VE_L_BL;?BH425)'38XWSI8;EBY:*2U?"9N:/,5-XWN[$KB;XG=+#D!,X2 MG<1!LA,^\7+T:>DG>4CO1'+I-XBV*JC-GWS=YF,(%=J63F*?V-&](SQ>=L2' M\4[B)/:1'[L_L=.#)_P]%D=\9.HXOZ_B_VGV MH^MEV+94?<4-,B9TF(^T]Q?L*^B6%#_K*B-MH($HH$#PDD%F4S)U@\/2U N+?(D6,JK-YR2\\[V&:5@Q*GYT%EJI+(4I^67KM.2%\ X*1^[3DI) M;./,=#&NK=+T4EX^=#'(%<5#SD078]NR9LG9Z&)3GB_67/F%!TXICT=BLK:-J?DP/'LZ5!2T-0Y'UT,9>5* M/F>DNR&LXH.#E)A?NAC#JC^@X*S4'<^F^9'%3$1>@*=/NLDO(22W/QF%'[M( M;^1^$B.YD_Q Q^7?4$L#!!0 ( +(XJ5ADK)E"TBT 8V @ / 86UL M>"UE>#DY7S$N:'1M[7UI<^/&=NCW5.4_]'/L6*J '&[:Y[HB2QI;N1J-,M+$ M=E*I5!-HDNT!T#062;R__IUSN@$"%"EJ).YL?_"()-#KV=?WO23P?_HG]KXG MN ?_LO>)3'SQT\7OE:.C:OW]._T1'GAGGGC?5MZ Q) M^G\RZ*LHX6%RTN>>)\/N,3OL/YY\1\-Z\CY[R?Q:253_N%;=D^%)(,-*3\AN M+SFNP\>V>JS$\A\X0EM%GH@J\ V,\[Z?#=%188*/B.-ZK9^&"?5<##[,&V2A(5P+.)>$PJW)?=\-@7G03GP->S:1YZ,A&5 MN,]=<=R/1.4AXOV3PMQUF+LXW8]G,%8[DC\Z,0_C2BPBV:'-/4@OZ1UW9%)Q MX7$1XDS_^B_U_=K)^W3^-^SG'5PZ7?X\-Q8AV(SNS%6^ MBH[_I4;_G4S>YX,&NK;RO9.1M3V[G E'YK]_CD MFN>].Q?F%=&*W/!I,/ 'C^RFQZ, )DL3Z7(_9I\%DKZ8?9!1G+#_3'D$2V:- M6J,%7X4\= %QX*$X]9-X@4?W&J2?*5P4J+XGX[[/!\<=7SR6-_=G&B>R,\C& MHB$+;J,""@_BXS6/ARU \V?!P1D'\61CV4"Y^A.O/0S%?1Y.&"P MM#!FB6(B[/*N8 \RZ;$/YZ<,+\UC*F02D5@&S.,)9YU(!2SI"<2C6+ &^_7B MZO+3+7-A;XA0+$%.PSP1J#!.(IZ *,! O(C4O0A@YAB&8S"Q&PGXS66=-'03 MJ4*'=?V!*P+X"M<8*=]A//38O8PEK0%>BN %">_"(+3*WY3?B7C XD'HP;($ MS V#PJ+IU]./O]=JS;T3V%L?#[ZP?N[[K-XHC\@3]IL07QG@/7RFKW$HF+B# MCZL.T80<29 _+H9+6DI@*<%<*<&EP6\>@42*\"J+1G M4<'F]J?--WE[!NX6A0$CU/;TX\^?+\]_N7" 8L9Q%?X_8$>& M:"+0U^K-$Y:=QX3U=3KCUT>;]$!L06U?A<=IZ(F(4&-N5CN'789N= M;.>:QQ[_ZQB$N*O?=]F./D/W1"]7?_).F(I(ILM^-3:7[.==@X41F2"!675R M@V.D#8ZL8T;HD'7R+V.=%'#"W@COJR[0.#D!EE<-6V>]O\7 5@Y** T!!'5Y M*/]!F,4\(?H^:M=!(!,$&#+;H4=.JPYI!^@]?G)YBL:[]H"%(HV4)[HB%(B> MH*X#^Q+ OP&''@0,H+ZR^$%V$L;)#I>I(66 ,XH(SM=1;@K"6!HAC,(_+FP* M7OLJ!D,5!QD-'$G^F:P%/-#B73N5/MD5<9I[Y&HP)M ,O4584X_#*GTN:7L> MZDX\QN^]")>?J <>>;2 0,9H'*RRW^"12.BE:9MEMDGVT ,.B%/!_R4L@/5D MM\?2,! )G WB'&!86R2X2WR*]Z70ZRR^B:,_"-\',@]Z;78DC%T4D, M,[H]@(0XP,O0=^7D=";&T_H/%?=2SLY43X0TQW\@&(?L[[X0#GQ=.;OX1&*T M)E+5G"SA\>4F3Q8 X9%]V%@H>*3%6[0_B9+B\ONR3!.@ O+A^2B XM*_B M$RKL*@+%DMX;C]B1GIIP>VB RJ25F]N;HLDHOVD8""#_T94&"=H$]4:A=O0* M%>(3;2P682R8 M169*92">@(#$2^KM#FZ9!\?PA^L#I8:Y\#;C8<'!F!5&]A MNIY>S>YCB8R)L>73R8WA V]166;LO?PLT)D*6!SU4MT5B(RCV?@ (>AB"^N%J4"(#127H N0GPCT@$"J26SQ=7 M?_S7Y\M/L\+6>Q&1)F2N'<0-$17VM%\]>#VL'[3>Q,!F?,KO3J] =?WTWZ>P MLCU04G/G% E=R=!-G;EY<]6I[*ENLIM?/UU<7_ZN!9%E*H^7($CT(^D[M+S, M$3^$HZ3'$R9Q59S40HX"-,C9QNV-+WVIWE;9!Z4\$I/.HQ2D'P\FE-KG#L>Q M\^'\=)=^_55P'UX[XR'W.,+DO?+3$,:&1:.@G#GK"J>*4A%/DYZ*C.JA);\, MBO,[R?53\KR3\0GE.Y"2<&(#^_@[;,!+W>3)[1EABK:#K^A%5MD=BH&><+7W M_X%CV "BEU9JLJLNW6AV\8Z)9*#5T(%%HIOZ/%'1(-M4(E'_P0EQ_RFI$873 MQ0V@DI6&,AE4V:F66O'*6$MKV\Z8LX 5AXKY(/B"+L'ON?1)/\ C"@$H0+B6 M:,C6\V:?F)M&$?P!5Z%5(I3Z)QP+J"0*!6XT[.%6C<9D5BU!YNT-8A#C>0BZ MG8Q[>-< 0WKD_()&,\C$GHU2(TBNX"E:RTF^EK59:1.!2WA_#)\:B3 M".XS);D[UPH+X#Q47$I&C;+"6-(+@8D)^NBHU M.LIS*H91+/0]E)UPU0EVS]5D]@LV4VP[O\_B),IQ4)F>^WP\5$'KW8F5)], MD%6$ [^=)@.2Y__GYN?_)8A,>!JE$3ZD?/8_=U\^WWYR- 9^#=5#B,80^ED] M2C@(?!J.Z']W$8)IOXQ[Q/]\>8_K&A\I-8S/ O01H0MXR;LCH5HCD5IM =MV M!6CF+XO9JDZS)\^1Q1JZ!109P]M"0Z0"(9(Q\6UPBW!SQ2BW:GY@9#**>"2< M8L@+;%R$ @_%V)GPV- F@VRS#P\^R@!.%FAZTX%MLKY0:% I4O6[W*X$/(/> MN4@3[ZBTG$2@3R5N[[&$*HCY-.#Z0Q6$:H^5L@@C:P3H'G MCY^!9\$E\!BQ($*82'U [IV+S[LE*$*6+3VX+ MY&W!ZF^#R6+*P?#$>]$P[Z8K*FT@#E\KO .K/.8^B$6Q3="Q"3I6-)T@FJ(4 MTI8^L,KCGO0\$7Z[L+HZ<2"3 ,,;Q$-I#"10#)YZ0/TN%/ @Z8H@L8'V&[$ M&)WVOR!/R007X@2Y.,-#B18L>G3DR3<93.9E:%[\@:,(]C0A0@O>Y0R%GM*> M3!<48E\@FVVT&##OK_H.
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end XML 16 amlx-20240509_htm.xml IDEA: XBRL DOCUMENT 0001658551 2024-05-09 2024-05-09 0001658551 false 8-K 2024-05-09 AMYLYX PHARMACEUTICALS, INC. DE 001-41199 46-4600503 43 Thorndike, St., Cambridge MA 02141 (617) 682-0917 false false false false Common Stock, $0.0001 par value per share AMLX NASDAQ false